Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Oct 15, 2026 is 59.44. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 44.44 — a change of 33.76% (higher).

EV/EBITDA

59.44

YoY

33.76%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Vcanbio Cell & Gene Engineering Corp is 2025 59.44 . EV/EBITDA (Enterprise Value to EBITDA) of Vcanbio Cell & Gene Engineering Corp was 2024 44.44 . It decreases by 33.76% higher compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
101.87 CNY
Jan 1, 2019
61.10 CNY
Jan 1, 2020
-559.41 CNY
Jan 1, 2021
34.35 CNY
Jan 1, 2022
43.20 CNY
Jan 1, 2023
46.46 CNY
Jan 1, 2024
44.44 CNY
Jan 1, 2025
59.44 CNY
The Vcanbio Cell & Gene Engineering Corp EV/EBITDA history
YEAREV/EBITDAYoY
59.44+33.76%
44.44-4.36%
46.46+7.55%
43.20+25.75%
34.35-106.14%
-559.41-1,015.62%
61.10-40.02%
101.87+14.17%
89.22-14.09%
103.86+160.27%
39.90-72.00%
142.50—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp Ltd is a biotechnology company based in Tianjin, China, operating within the healthcare sector. The company has been publicly traded since its IPO on May 4, 1993, and is listed under the ticker 600645.SS with ISIN CNE000000545. It employs 2,332 full-time staff and focuses on the development of life sciences technology. Vcanbio engages in cell culture, gene detection, and storage services, as well as the production and sale of cytokines culture solutions, cosmetics, and detection reagents. The company primarily serves domestic markets in China, with its headquarters located in Tianjin. Its website is http://www.vcanbio.com. The firm's business activities include the development and application of biotechnology solutions, though specific details on product names, acquisitions, or additional financial figures are not provided in the available information. Vcanbio operates as a public company with a presence in the Chinese biotechnology industry, emphasizing innovation in cell and gene engineering. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

EV/EBITDA (Enterprise Value to EBITDA) of Vcanbio Cell & Gene Engineering Corp is 59.44 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Vcanbio Cell & Gene Engineering Corp changed from 44.44 to 59.44, representing a 33.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Vcanbio Cell & Gene Engineering Corp with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Vcanbio Cell & Gene Engineering Corp

All Key Metrics — Vcanbio Cell & Gene Engineering Corp